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Abstract
The Niemann-Pick disease, type C1 (NPC1) gene encodes a transmembrane protein involved in cholesterol efflux from the
lysosome. SNPs within NPC1 have been associated with obesity and type 2 diabetes, and mice heterozygous or null for NPC1
are insulin resistant. However, the molecular mechanism underpinning this association is currently undefined. This study
aimed to investigate the effects of inhibiting NPC1 function on insulin action in adipocytes. Both pharmacological and
genetic inhibition of NPC1 impaired insulin action. This impairment was evident at the level of insulin signalling and insulin-
mediated glucose transport in the short term and decreased GLUT4 expression due to reduced liver X receptor (LXR)
transcriptional activity in the long-term. These data show that cholesterol homeostasis through NPC1 plays a crucial role in
maintaining insulin action at multiple levels in adipocytes.
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Introduction
Metabolic diseases such as insulin resistance and type 2 diabetes
(T2D) are major and escalating health concerns. Despite extensive
research we have a rudimentary understanding of the molecular
mechanisms that underpin insulin resistance in insulin target
tissues. Recent advances in large-scale analysis platforms have
offered the opportunity to reveal novel links between genes and
disease phenotypes. For example, genome wide association studies
(GWAS) have identified more than 70 genetic loci that associate
with T2D [1–6], but for many of these the molecular basis for the
association remains unknown. Studies to interrogate how genes
associated with these loci impact whole body glucose metabolism
are required.
One example of an associated gene is Niemann-Pick disease,
type C1 (NPC1) which encodes a transmembrane protein that has
been primarily studied in the context of Niemann-Pick type C
(NPC) disease. NPC disease is a rare lysosomal storage disease
characterized at the cellular level by the accumulation of
cholesterol and sphingolipids within the late endosomal/lysosomal
compartment [7]. NPC1 cooperates with NPC2 in the egress of
cholesterol from the late endosomal/lysosomal system [8,9],
though the vast majority of NPC disease cases arise from
mutations in NPC1 [10]. Single nucleotide polymorphisms (SNPs)
within the NPC1 gene have been associated with early onset and
morbid obesity and, independently of obesity, insulin resistance in
humans [11–13]. Further, mice heterozygous for NPC1 have
increased susceptibility to weight gain and display abnormal
metabolic characteristics such as hyperinsulinemia and glucose
intolerance [14], and this impairment in glucose tolerance is
independent of body weight [15]. Taken together, these data
suggest a role for NPC1 function in maintaining metabolic
homeostasis and in predisposition to metabolic diseases.
NPC1 has been reported to influence insulin signalling in the
spontaneous murine (nih) model of NPC disease [16]. Insulin acts
largely via activating the serine/threonine Kinase Akt (PKB)
through its phosphorylation at S473 and T308. NPC1 (nih) mice
exhibited reduced phosphorylation of Akt and its substrate GSK3b
in the brain, which was attributed to a marked decrease in insulin
receptor substrate 1 (IRS1) expression. Also, pharmacological and
genetic inhibition of NPC1 function reduced phosphorylation of
Akt in endothelial cells due to inhibition of mTORC2 activity,
which is responsible for phosphorylating Akt at S473 [17]. In light
of the GWAS association, the metabolic profile of NPC1 null mice
and these molecular data, we speculated that disruption of NPC1
function may impact metabolic homeostasis through reduced
insulin-stimulated Akt activation and that the association between
NPC1 and insulin resistance may be due to effects on insulin action
in its target tissues. We report that inhibition of NPC1 activity in
an adipocyte cell model reduced insulin-stimulated glucose uptake
through disruption of multiple sites: Akt activation, exocytosis of
the insulin-responsive glucose transporter GLUT4, and total levels
of GLUT4.
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Materials and Methods
Cell Culture
3T3-L1 fibroblasts were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Life Technologies) supplemented with 10%
foetal calf serum (Thermo Scientific) and 1% Glutamax (Life
Technologies) at 37uC in 10% CO2. Fibroblasts were grown to
confluence before differentiation into adipocytes in DMEM
containing 100 ng/ml dexamethosone, 100 ng/ml biotin, 2 mg/
ml insulin and 50 mM 3-isobutyl-1-methyl-xanthine (IBMX) for
3 days. Following this cells were post differentiated for a further
3 days in DMEM containing 2 mg/ml insulin. 3T3-L1 adipocytes
were used for experiments 10–14 days after initiation of differen-
tiation. HA-GLUT4 expressing 3T3-L1 adipocytes were generat-
ed as previously described [18]. Cells were treated for specified
periods of time with 0.1% DMSO as a vehicle control or 10 mg/
ml U18666a (Sigma-Aldrich). U18666a was not present during the
basal period (DMEM, Glutamax, 0.2% BSA). Incubations with
the LXR agonist GW3965 at 10 mM (Sigma-Aldrich) were
performed during the final 16 h of 72 h U18666a treatment.
Control (K1) and NPC1 knockout (2–2) CHO cells were a kind gift
from Dr. Andrew Brown (UNSW, Sydney, Australia). CHO cells
were cultured in DMEM F-12 nutrient medium supplemented
with 10% foetal calf serum and 1% Glutamax at 37uC in 10%
CO2.
Transient Transfection and siRNA Mediated Knock Down
NPC1-YFP was kindly provided by Dr. Hongyuan Robert Yang
(UNSW, Sydney, Australia). NPC1-YFP was transfected into
CHO cells using Lipofectamine LTX (Life Technologies) follow-
ing the manufacturer’s guidelines. For siRNA experiments
approximately 2 million cells were used for each nucleofection
with scrambed siRNA as a control (sense 59-
CAGTCGCGTTTGCGACTGGTT-39) or siRNA to NPC1
(sense 59-GGGAAAGAAUUCAUGAAAUUU-39) (Thermo Sci-
entific) using the Amaxa Kit and reagents following the
manufacturers guidelines (Lonza). Cells were reseeded onto
matrigel (BD Biosciences) coated plates and experiments were
performed 4 d later.
Preparation of Whole Cell Lysates and Western Blotting
Cells were serum starved in serum-free media for 2 h before
incubation with 100 nM insulin for 20 min. Cells were lysed in
lysis buffer (2% w/v SDS in phosphate buffered saline (PBS),
pH 7.4, protease inhibitors (Roche), 1 mm sodium pyrophos-
phate, 2 mm sodium vanadate, 10 mm sodium fluoride) sonicated
for 12s and centrifuged at 13,0006g. The protein concentration of
the supernatant was determined by BCA assay (Thermo Scien-
tific). 10 mg samples of protein were resolved by SDS-PAGE and
transferred to PVDF membranes. Membranes were blocked in 5%
skim milk powder in TBS-T (0.1% v/v Tween-20 in tris-buffered
saline) for 1 h followed by an overnight incubation at 4uC with
specific 1u antibody solutions. Membranes were incubated with an
appropriate secondary antibody for 1 h before signals were
detected using ECL (Thermo Scientific) or on the Odyssey
infrared imaging system (LI-COR). Anti-Akt, anti-pT473 Akt and
anti-pT308 Akt antibodies were obtained from Cell Signaling
Technology. Anti-IRS1 antibody, anti-insulin receptor b antibody
and anti-14-3-3 antibodies were from Santa Cruz Biotechnology.
Anti-AS160 was from Upstate, anti-pT642 AS160 was from
Symansis, anti-NPC1 antibody was from Abcam and anti-TfR
antibody was from Zymed. IRAP, GLUT1 and GLUT4
antibodies were generated in-house.
Filipin Staining
For imaging of U18666a-treated 3T3-L1 adipocytes cells were
seeded into individual collagen type IV coated wells of m-Slide
8 well chambered slides (Ibidi) prior to U18666a treatment as
described above. Cells were at room temperature with 3%
paraformaldehyde (PFA) in PBS for 30 minutes. PFA was
quenched with 20 mM glycine and cells were blocked with 2%
BSA in PBS. Filipin (Sigma-Aldrich) was added to cells at 125 mg/
ml at room temperature for 30 min. Cells were imaged in PBS
with 5% glycerol (Sigma) and 2.5% 1,4-diazabicyclo[2.2.2]octane
(Sigma) on a Leica DMI 6000 SP8 MP microscope (Leica) using a
636/1.20 water corrected objective. Z-stacks were acquired for
the entire sample thickness up to 50 mm with a voxel size of
0.1260.1260.43 mm. The Filipin signal was imaged using
multiphoton excitation at 725 nm and emission was detected at
450–550 nm.
For imaging of siRNA-treated cells, 3T3-L1 adipocytes were
electroporated with scrambled siRNA or siRNA directed to NPC1
as described above. Cells were and seeded onto matrigel coated
42 mm coverslips (#1.5). Cells were fixed and stained as above.
Cells were washed, mounted and imaged on a Leica DMI 6000
SP8 confocal microscope (Leica) using a 636/1.20 water corrected
objective. The Filipin signal was imaged using 405 nm excitation
and emission was detected at 450–550 nm, voxel size
0.0760.0760.34 mm.
Cholesterol Assay
3T3-L1 adipocytes were homogenised in HES buffer (10 mM
Hepes, pH 7.4, 1 mM EDTA, 250 mM sucrose, protease
inhibitors (Roche)) by 12 strokes of a dounce homogeniser. Cell
debris was pelleted at 7006g for 10 min and a total membrane
preparation acquired by centrifugation at 235,0006g for 75 min.
Lipid was extracted by chloroform:methanol extraction. Briefly,
membrane preparation was added to chloroform:methanol (2:1)
mix, vortexed and shaken for 10 minutes. ddH2O was added and
samples were centrifuged for 10 minutes to generate a clear
interface. The lower phase was removed and evaporated to
dryness. Lipid residue was reconstituted in 100 ml 10% (v/v)
Triton X-100 in Isopropanol and cholesterol levels determined
using an Amplex Red based cholesterol detection assay following
the manufacturer’s instructions (Life Technologies).
2-[3H]deoxyglucose Uptake Assay
3T3-L1 adipocytes were serum starved in serum-free DMEM
for 2 hours before being washed in PBS (x3) and incubated in
Krebs Ringer buffer (KRP) (0.6 mM Na2HPO4, 0.4 mM
NaH2PO4, 120 mM NaCl, 6 mM KCl, 1 mM CaCl2, 1.2 mM
MgSO4 and 12.5 mM Hepes (pH 7.4)) with 0.2% BSA. Cells were
stimulated with 100 nM insulin for 20 min. To determine non-
specific glucose uptake, 25 mM cytochalasin B was added into the
wells before addition of 2-[3H]deoxyglucose. During the final
5 min, 2-deoxyglucose transport was initiated by addition of 2-
[3H]deoxyglucose (PerkinElmer). Following three rapid washes in
ice-cold PBS, cells were solubilized in 1% (v/v) Triton X-100 in
PBS. Scintillation counts were normalized for protein content.
Subcellular Fractionation
3T3-L1 adipocytes cultured in 15cm plates were harvested in
HES buffer and dounce homogenised. Subcellular fractionation
was carried out as previously described [19].
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HA-GLUT4 Assay
The determination of plasma membrane HA-GLUT4 levels
was carried out as previously described [20].
qPCR
3T3-L1 adipocytes cultured in 6 well plates were lysed in 1 mL
TRIzol (Life Technologies). 0.2 mL of chloroform was added
samples were mixed well. Samples were centrifuged at 12,0006g
for 15 min at 4uC and the aqueous phase collected. Following
addition of 0.5 mL 100% isopropanol, samples were incubated for
10 min at RT and centrifuged at 12,0006g for 10 min at 4uC. The
pellet was washed with 1 mL 75% ethanol and centrifuged as
7,5006g for 5 min at 4uC. The RNA pellet was resuspended in
RNase-free water and incubated at 60uC for 10–15 min. A master
mix was prepared for the reverse-transcription reaction comprised
of 10 x Buffer RT, 5 mM dNTP, 10 mMOligo dT primer, 10 U/
ml RNase inhibitor, Omniscript Reverse Transcriptase (Qiagen)
and RNase-free water. 2 mg Template RNA was added to the
master mix which was then briefly vortexed, centrifuged and
incubated for 60 min at 37uC. qPCR was performed using the
LightCycler 480 (Roche) using the LightCycler480 Master reagent
(Roche), according to the manufacturer’s instructions. Primers for
target genes were 59-gcagatcaagcatcccaact-39 and 59- ccaga-
gaatgtttcattgtcca-39 for ABCA1, 59- tgctctgggtaccatgacatc-39 and
59- cccacaaatgtcgcaacc -39 for ABCG1, 59-agaccctggaggctaaggac-39
and 59-agagccttcatcttcgcaat-39 for APOE, 59-catgagggaaatcaat-
gatcg-39 and 59-ctaaagctgagagagtgtgagagc-39 for TfR, 59-agtgttca-
tatctacgaaccgtacc-39 and 59-tcaatggcgatctgtaagtcc-39 for NPC1, 59-
gacctgtcctcaagattggtg-39 and 59-gatggtgtgccttcatctgtc-39 for IRAP,
59- cagccggcacagctagag -39 and 59- agcactgctcctcccaca -39 for
GLUT1, 59- gacggacactccatctgttg -39 and 59- gccacgatggagacatagc
-39 for GLUT4 and 59-ttcttcataaccacagtcaagacc-39 and 59-
accttccgtaccacatccat-39 for CYPB.
Results
Genetic Ablation of NPC1 Inhibited Insulin Signalling
To initially assess the role of NPC1 activity on insulin signalling
we utilised CHO 2–2 cells, an NPC1 knockout cell line [21].
These cells do not express NPC1 due to a frame-shift in the gene
transcript (Figure 1A). We did not observe any changes in the total
levels of the insulin signalling molecules Akt or Akt substrate
AS160 (TBC1D4) between this cell line and wild type CHO (K1)
cells (Figure 1B). However, differences were apparent upon insulin
stimulation. In wild type CHO (K1) cells, insulin stimulated
phosphorylation of Akt at S473 and T308 and AS160 at T642.
This effect was reduced in 2–2 cells (Figure 1C).
We validated the specificity of this approach by rescuing NPC1
expression. NPC1-YFP was transfected into both K1 and in 2–2
cells (Figure 1A). NPC1 overexpression enhanced phosphorylation
of Akt and AS160 in K1 cells suggesting that increasing NPC1
activity in wild type cells can augment insulin responses. Rescue of
NPC1 expression in 2–2 cells restored insulin-stimulated phos-
phorylation of Akt at S473 and T308 and AS160 at T642 towards
the levels observed in K1 cells, although the degree of
phosphorylation at these sites did not fully revert to levels in
control cells (Figure 1C). Overall, introduction of exogenous
NPC1 improved signalling in both wild type and NPC1 KO cells.
Inhibition of NPC1 Impaired Insulin Signalling in 3T3-L1
Adipocytes
Having shown that NPC1 regulates insulin signalling in CHO
cells, we investigated whether this link also exists in 3T3-L1
adipocytes, a more physiologically relevant cell model for insulin
signalling. We first took a pharmacological approach to reduce
NPC1 activity. U18666a is an agent used to induce an NPC
disease phenotype and is reported to interact directly with NPC1
[22]. Incubation of adipocytes with U18666a for 24, 48, and 72 h
resulted in redistribution of cholesterol from the plasma mem-
brane to intracellular structures most likely due to the accumu-
lation of cholesterol in lysosomes (Figure 2A). Treatment with
U18666a also led to increased concentrations of cholesterol within
the crude membrane fraction (Figure 2B). Both these readouts
indicated effective NPC1 inhibition [7].
We used this model to interrogate the effect of NPC1 inhibition
on insulin signalling in 3T3-L1 adipocytes. We treated 3T3-L1
adipocytes with U18666a for 24, 48, and 72 h prior to examining
insulin signalling. Insulin-stimulated phosphorylation of Akt (T308
and S473), and AS160 (T642) was substantially reduced in
U18666a treated cells (Figure 2C). To investigate why we observed
this defect in insulin signalling, we measured the expression levels
of proteins comprising key nodes within the insulin signalling
pathway (Figure 2D). Total Akt levels were unchanged with
U18666a treatment. However, expression of both the insulin
receptor (IR) and insulin receptor substrate 1 (IRS1) were reduced
in adipocytes incubated with U18666a for prolonged periods (48–
72 h). However, these changes in total expression levels are
unlikely to fully account for the reduced Akt phosphorylation since
the change in IR and IRS1 occurred much later than the defect in
Akt phosphorylation. In fact changes in IR and IRS1 correspond-
ed better with redistribution of cholesterol from the PM to
intracellular sites (Figure 2A).
NPC1 Activity was Required for Full Akt Activation
To confirm our observations using a pharmacologic inhibitor of
NPC1 we next used siRNA knock down to determine if this
achieved the same outcome. Introduction of an NPC1-targetted
siRNA into adipocytes was sufficient to achieve an approximately
50% reduction in cellular NPC1 levels and inhibit NPC1 function
as indicated by the accumulation of cholesterol at intracellular sites
(Figures 2E, F). Consistent with our studies with U18666a,
phosphorylation of Akt at both 308 and 473 was reduced by
approximately 50% (Figures 2G). In addition, AS160 phosphor-
ylation at T642 was decreased in NPC1 knock down cells
(Figures 2G). Intriguingly we did not observe any significant
change in the levels of either IR or IRS1 with NPC1 siRNA
(Figure 2F) in contrast to that seen with U18666a. This is
consistent with our observation in drug treated cells the
impairment in Akt signalling precedes the reduction in IR and
IRS1 levels. To further confirm that defects at Akt were not due to
reduced IRS levels we next examined the regulation of Akt by
PDGF in 3T3-L1 adipocytes overexpressing the PDGF receptor.
Unlike insulin, PGDF activates Akt through a direct interaction
between the PDGF receptor and PI3K [23] and so initiation of
Akt signalling in response to PDGF is independent of IRS1. We
observed a reduction in PDGF-stimulated Akt activation in
U18666a treated cells (Figure 2I). Based on these findings we
conclude that that inhibition of NPC1 influences Akt function
independently of its effects on IRS1 protein abundance.
Inhibition of NPC1 Reduced Insulin-stimulated Glucose
Uptake in 3T3-L1 Adipocytes
Since we observed considerable impairment of insulin signalling
in response to NPC1 inhibition, we next measured whether this
had downstream consequences; specifically on insulin-stimulated
glucose transport. Insulin stimulates glucose transport in adipo-
cytes through promoting trafficking of GLUT4 to the cell surface
[24]. U18666a treatment substantially reduced insulin-stimulated
Role of NPC1 in Adipocyte Insulin Action
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2-deoxyglucose uptake, and this phenotype worsened over the
time course of NPC1 inhibition (Figure 3A). However, the extent
of this defect was blunted compared to the level of Akt
phosphorylation (Figure 2C). In addition, 2-deoxyglucose uptake
in the absence of insulin was increased with U18666a treatment
over time (Figure 3A). Although no defect in 2-deoxyglucose
transport in NPC1-knockdown cells was observed at 100 nM
insulin, there was a blunted effect at 0.1 nM (Figure 3B),
indicating reduced sensitivity to insulin.
Inhibition of NPC1 Altered GLUT4 Trafficking
Considering that basal and insulin-stimulated glucose uptake
was affected by U18666a treatment, we hypothesised that GLUT4
trafficking to the PM in response to insulin would be altered in
U18666a treated cells. We isolated PM fractions from unstimu-
lated and insulin-stimulated adipocytes treated with or without
U18666a and determined the levels of GLUT4 and IRAP, a
protein that co-traffics with GLUT4 [25](Figure 3C). A striking
observation was the reduction in PM GLUT4 and IRAP under
basal conditions. PM caveolin levels were also reduced in
U18666a treated cells. Although the major effect of U18666a
treatment appeared to be in reducing GLUT4 levels in PM
fractions from both basal and insulin-stimulated adipocytes, there
also appeared to be a reduction in the fold-stimulation of GLUT4
translocation to the PM in U18666a-treated cells. To confirm this
defect in GLUT4 translocation, we performed a complementary
assay in 3T3-L1 adipocytes overexpressing GLUT4 with a HA-
epitope in the primary exofacial loop (HA-GLUT4) to measure
PM levels of GLUT4 [20]. The advantage of this assay is that PM
HA-GLUT4 levels can be readily expressed relative to total HA-
GLUT4 expression levels allowing determination of the level of
HA-GLUT4 translocation to the PM independent of any effects
on GLUT4 expression which may confound interpretation when
assaying endogenous GLUT4 levels. PM GLUT4 was increased in
the basal state and decreased in the insulin-stimulated state in
response to U18666a. The extent of increased PM HA-GLUT4
under unstimulated conditions and inhibition of insulin-stimulated
HA-GLUT4 translocation was more pronounced with increasing
U18666a treatment length (Figure 3D). Overall, U18666a
treatment resulted in modest but significant changes in GLUT4
trafficking under both unstimulated and insulin stimulated
conditions.
Total GLUT4 Levels were Reduced by U18666a Treatment
Despite observing changes in GLUT4 trafficking, the major
observation from our subfractionation studies was reduced
GLUT4 in the PM fraction. We next determined whether this
was due to mislocalisation of GLUT4 or to a reduction in total
levels of GLUT4. GLUT4 protein levels were considerably
decreased, after 72h of U18666a treatment (Figure 4A). We
compared this to effects on the levels of other trafficking proteins.
Intriguingly the levels of IRAP and the transferrin receptor (TfR)
were also reduced in cells exposed to U18666a for 72 h, but to a
lesser extent than GLUT4. In contrast to effects on GLUT4, levels
of another GLUT isoform, GLUT1, was increased in the
U18666a treated cells (Figure 4A), indicating that U18666a
treatment did not lead to a global reduction in trafficking protein
expression.
Inhibition of NPC1 Reduced LXR-mediated GLUT4
Transcription
To assess whether the change in GLUT isoform, IRAP and TfR
protein expression was mediated transcriptionally, we measured
transcript levels in control and U18666a treated cells by qPCR.
U18666a resulted in down-regulation of GLUT4 mRNA to 32% of
that of control cells and of TFR to 36% of that in control cells
(Figure 4B). In contrast, GLUT1 transcription was up-regulated
approximately 2-fold while IRAP transcript levels were unchanged
implying that changes in IRAP protein were not mediated
transcriptionally. We next measured mRNA levels of these genes
in cells treated with NPC siRNA. This analysis confirmed NPC1
knockdown and also revealed a significant decrease in GLUT4
expression which did not translate to a change in GLUT4 protein
levels in these cells (89.9% 67.1% S.E.M, n= 4, p = 0.25 by two
sample t-test) (Figures 4C, D). The extent of GLUT4 down-
regulation at the mRNA and protein level was substantially less
than observed in U18666a-treated cells. GLUT1, TFR and IRAP
transcripts were not altered in NPC1 knockdown cells (Figure 4C).
It has previously been reported that the activity of the liver X
receptor (LXR), a nuclear receptor that recognises oxysterol
ligands, is reduced under NPC1 inhibition [26]. Further, LXR has
been implicated in regulating GLUT4 expression [27]. Therefore
we tested whether LXR activity was reduced in adipocytes treated
with U18666a through measuring the expression of classical LXR
target genes ABCA1, ABCG1, and APOE. These genes were down-
regulated by 44%, 64%, and 53% respectively, indicative of
reduced LXR activity (Figure 4E). To test whether GLUT4
Figure 1. NPC1 knockout inhibited insulin signalling in CHO cells. (a) Total cell lysates of K1 CHO cells and 2–2 CHO cells were
immunoblotted with anti-NPC1 antibody to determine expression levels of endogenous NPC1 and overexpressed NPC1-YFP. (b) Total cells lysates of
K1 CHO cells and 2–2 CHO cells were immunoblotted with anti-Akt and AS160 antibodies to compare expression levels between K1 and 2–2 CHO
cells. (c) Total cell lysates from unstimulated and insulin-stimulated cells (100 nM, 20 min) were immunoblotted with phospho-T308 Akt, phospho-
S473 Akt, phospho-T642 AS160 and 14-3-3 antibodies to assess insulin signalling.
doi:10.1371/journal.pone.0095598.g001
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Figure 2. Pharmacological and genetic inhibition of NPC1 reduced insulin signalling in 3T3-L1 adipocytes. NPC1 was inhibited in 3T3-
L1 adipocytes through treatment with U18666a or through siRNA-mediated knockdown of NPC1. (a) Subcellular localisation of cholesterol in 3T3-L1
adipocytes after treatment with U18666a for indicated times was visualised by Filipin staining (scale bar = 10 mm), bottom panel. Corresponding
bright field images are provided (top panel). Images are representative of n$300 cells viewed per condition over 3 experiments. (b) Total membrane
cholesterol levels within the total membrane fraction. Data are mean 6 S.E.M, n = 3 independent experiments, one-way ANOVA. (c) Insulin signalling
was assessed by immunoblotting total cell lysates of unstimulated and insulin-stimulated (100 nM, 20 min) 3T3-L1 adipocytes for phospho-T308 Akt,
phospho-S473 Akt, phospho-T642 AS160 and 14-3-3. (d) Total protein expression of key proteins in the insulin pathway determined by
immunoblotting for IRS-1, IRb and Akt. (e) Subcellular localisation of cholesterol after treatment with scrambled or NPC1 siRNA was visualised by
Filipin staining (scale bar = 10 mm). Images are representative of n$300 cells viewed per condition over 3 experiments. (f) The extent of siRNA
mediated knockdown of NPC1 and the effect of knockdown on expression of proximal insulin signalling components was measured by probing for
NPC1, IRS-1, IRb and Akt. (g) The effect of NPC1 knock-down on insulin signalling was assessed by immunoblotting with phospho-T308 Akt, phospho-
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expression was decreased as a function of reduced LXR activity we
utilised GW3965, which activates LXR independently of cellular
sterol status. GW3965 increased the expression of the classic LXR
target genes as well as GLUT4 in control cells (Figure 4E).
Applying GW3965 to cells pre-treated with U18666a for 72 h
rescued the expression of ABCA1 and ABCG1 above the levels
observed in untreated control cells, towards levels observed in
control cells treated with GW3965. APO-E and GLUT4 expression
was increased towards levels observed in untreated control cells.
For GLUT4, the increase in expression in response to GW3965
was significantly greater in cells pretreated with U18666a than in
control cells (Figure 4E, F). This rescue of GLUT4 mRNA levels
also resulted in increased protein expression (Figure 4G). To
ensure that reduced LXR activity was a result of NPC1 inhibition
by U18666a and not an off target effect we also assessed LXR
target gene expression in NPC1 knockdown cells. NPC1
knockdown altered LXR activity cells as ABCA1 and ABCG1
transcript levels were significantly reduced (Figure 4H). However,
APOE levels were not changed. Nevertheless, these data indicate
that decreased LXR activity partially accounts for reduced GLUT4
gene expression upon NPC1 inhbition.
S473 Akt, phospho-T642 AS160 and 14-3-3 antibodies. (h) The levels of insulin-stimulated pS473 and pT308 of Akt in cells NPC1 knockdown cells was
quantified relative to control cells. Data are mean 6 S.E.M, n = 3 independent experiments, two-sample t-test. (i) 3T3-L1 adipocytes overexpressing
PDGF receptor were treated with U18666a for 72 hr prior to assessment of insulin and PDGF-mediated (20 ng/mL, 20 min) signalling. Signalling was
assessed by immunoblotting with phospho-T308 Akt, phospho-S473 Akt and 14-3-3 antibodies. All data are representative of at least n = 3
independent experiments, significance calculated compared to control cells, n.s = non-significant, *, = p,0.05 ** =p,0.01 *** =p,0.001, statistical
tests as indicated.
doi:10.1371/journal.pone.0095598.g002
Figure 3. Inhibition of NPC1 repressed insulin-stimulated glucose uptake. (a) 3T3-L1 adipocytes were treated with U18666a for indicated
periods of time before radiolabelled 2-deoxy-D-glucose uptake assays were performed on basal and insulin-stimulated cells. Data are mean 6S.E.M,
n = 4 independent experiments. (b) 3T3-L1 adipocytes electroporated with scrambled (Scr) or siRNA directed to NPC1 (NPC1) were subjected to
radiolabelled 2-deoxy-D-glucose uptake assays under basal and insulin-stimulated conditions. Insulin doses as indicated. Data are mean6S.E.M, n = 3
independent experiments. (c) Plasma membrane (PM) levels of IRAP, GLUT4 and Caveolin 1 in unstimulated and insulin-stimulated (100 nM, 20 min)
adipocytes were determined by immunoblotting. (d) PM levels of HA-GLUT4 was measured using a fluorescence based assay in 3T3-L1 adipocytes
overexpressing HA-GLUT4 treated with U18666a for indicated periods of time. Data are mean 6S.E.M, n = 3 independent experiments. Significance
calculated by two-way ANOVA. Comparisons to unstimulated cells (a, b, d) indicated by n.s = non-significant, * = p,0.05 ** = p,0.01 *** =p,0.001
**** = p,0.0001. Comparisons to insulin-stimulated cells (a, b, d) indicated by n.s = non-significant, #=p,0.05 ##=p,0.01 ###=p,0.001
####=p,0.0001.
doi:10.1371/journal.pone.0095598.g003
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Figure 4. Inhibition of NPC1 reduced GLUT4 expression via lower LXR activity. (a) Total protein levels of IRAP, Transferrin, GLUT1 and GLUT4
were determined by immunoblotting of whole cell lysates from cells with U18666a for indicated times. (b) GLUT1, GLUT4, IRAP, and TFR mRNA levels
in 3T3-L1 adipocytes treated with U18666a for 72 h were determined by qPCR and presented relative to expression in control cells. Data are mean
6S.E.M, n = 3–5 independent experiments. (c) NPC1, GLUT1, GLUT4, IRAP and TFR mRNA levels in 3T3-L1 adipocytes treated with NPC1 siRNA were
determined by qPCR and presented relative to expression in control cells. Data are mean 6S.E.M, n = 3 independent experiments. (d) Total protein
levels of NPC1 and GLUT4 were determined by immunoblotting of whole cell lysates from control and NPC1 knockdown cells. (e) mRNA levels of
ABCA1, ABCG1 and APO-E and GLUT4 were determined by qPCR. Control and U18666a (72 h) pre-treated adipocytes were treated with the LXR
agonist GW3965 (10 mM) for 16 h. Data are mean 6S.E.M and expressed relative to mRNA levels for each gene in control cells. All data are n = 3–5
independent experiments. (f) Percentage change in GLUT4 mRNA levels following GW3095 addition was calculated from (f). (g) Total GLUT4 protein
levels were determined by immunoblotting of whole cell lysates from control cells and cells treated with U18666a and/or GW3095 as indicated. (h)
ABCA1, ABCG1 and APOE mRNA levels in 3T3-L1 adipocytes treated with NPC1 siRNA were determined by qPCR and presented relative to expression
in control cells. Data are mean 6S.E.M, n = 3 independent experiments. Significance calculated by two sample t-test (b,c,f,h) or two-way ANOVA (e)
and indicated p values are compared to control cells n.s = non-significant, * = p,0.05 ** = p,0.01 *** = p,0.001 **** =p,0.0001 or cells treated with
U18666a (f) n.s = non-significant, #=p,0.05 ####=p,0.0001 (e).
doi:10.1371/journal.pone.0095598.g004
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Discussion
The molecular mechanisms of insulin resistance remain
unresolved. Recent genome-wide studies have begun to reveal
associations of genetic loci with insulin resistance. Indeed, GWAS
data and genetic studies in mice have uncovered a link between
insulin resistance and NPC1 [4]. Although this gene has been
previously implicated in insulin resistance and glucose intolerance
[14], the mechanism underpinning this association is undefined.
Here we report that pharmacological or genetic inhibition of
NPC1 function causes considerable defects at four major nodes of
insulin signalling to glucose transport; at the level of IRS1
expression, Akt activation, GLUT4 trafficking and GLUT4
transcription. Additionally, these nodes appear to be differentially
sensitive to NPC1 inhibition. These data strongly implicate NPC1
function and cholesterol homeostasis in the maintenance of insulin
sensitivity in adipocytes.
One of the major phenotypes associated with reduced NPC1
levels or activity was reduced insulin signalling. Insulin-stimulated
Akt and AS160 phosphorylation were reduced in an NPC1 KO
CHO cell line (2–2) and in 3T3-L1 adipocytes in which NPC1
levels were depleted using siRNA (Figure 1C and 2G, H). The fact
that this was observed in two cell lines supports the concept that
NPC1 function is required in multiple cell types to maintain
insulin responsiveness. U18666a treatments further disrupted
insulin signalling to Akt and AS160 (Figure 2C), but also led to
decreased levels of the insulin receptor and IRS1 (Figure 2D). This
matches observations from NPC12/2 mice [16]. However, we
did not observe the same reduction in these proximal signalling
molecules in siRNA treated cells (Figure 2F). We speculate that
this discrepancy may be due to the severity of NPC1 inhibition,
with prolonged U18666a treatment possibly more potently
inhibiting NPC1 function than the partial knockdown with
siRNA. We observed a reduction in PM cholesterol and an
increase in intracellular membrane cholesterol levels following
U18666a treatment and siRNA-mediated NPC knock down
(Figures 2A, B, E). However, only under conditions where PM
cholesterol is undetectable relative to internal staining do we begin
to observe reductions in IR and IRS1 levels (Figure 2A, D –48 h,
72 h). However, we cannot rule out that U18666a is having effects
other than on NPC1, which may account for this difference. For
example, U18666a is known to inhibit sterol synthesis [28], which
could exacerbate the cholesterol trafficking defects observed in
U18666a treated cells (Figure 2A). However, considering that
cholesterol trafficking defects and IRS1 levels appear to correlate it
may be that cholesterol-rich caveolae, within which IR resides
[29], were disrupted by U18666a treatment. We observed a large
reduction in caveolin at the PM in U18666a treated cells
(Figure 3B) but no change in total cellular caveolin (data not
shown), indicative of increased internal caveolin which has been
reported to occur in response to PM cholesterol depletion [30].
Since there is evidence for a role for caveolin in stabilising IRS1
[31–33] and for caveolin as a promoter of insulin signalling [34],
we favour the possibility that reduced IR and IRS1 levels are
caused by a loss of PM cholesterol and subsequent loss of lipid
rafts.
In addition to these IR and IRS1 effects, we also detected
specific inhibition of Akt phosphorylation which was IRS1-
independent. We provide several avenues of evidence for this
conclusion. Firstly, we observed reduced Akt phosphorylation
prior to impaired IRS1 expression in U18666a-treated cells,
although we cannot rule out that IRS1 is mislocalised at earlier
time points (Figure 2C and 2D). Secondly, a reduction in phospho-
Akt was detected in siRNA-treated cells without changes in IR and
IRS1 levels (Figures 2F, G). Thirdly, PDGF-dependent Akt
signalling was also reduced (Figure 2I). These data indicate that
NPC1 activity is required for complete activation of Akt and that
this requirement is independent of the alterations in IRS1 protein
levels. These findings shed new light on insulin signalling defects in
the NPC12/2 mice, which had been previously attributed to
solely reduced IRS1 expression [16]. Since we observed IRS1-
independent inhibition of Akt phosphorylation in response to
NPC1 inhibition, a defect is likely to lie at the level of
phosphatidylinositol-3-kinase (PI3K) or at the upstream kinases
of Akt, PDK1 and/or mTORC2. A number of components of this
signalling nexus have been localised to cholesterol-rich lipid raft
domains including phosphatidylinostol-2-phosphate (PIP2) [35–
37] the substrate for PI3K and both PDK1 [38] and mTORC2
[39]. Further, PTEN, a negative regulator of Akt phosphorylation
has been reported to be excluded from these domains [38]. Taken
together, one possibility for the pronounced defect in insulin
signalling downstream to Akt in the context of NPC1 inhibition is
the loss of the localisation of these signalling molecules upon
disruption of cholesterol trafficking.
Downstream of Akt signalling we also observed a defect in
insulin-stimulated glucose transport following U18666a treatment
(Figure 3A) and at low dose insulin in NPC1 knockdown cells
(Figure 3B) indicative of NPC1 inhibition reducing insulin
sensitivity. The time lag between reduced signalling and the
defects in GLUT4 translocation and glucose uptake observed in
U18666a-treated cells is of interest (Figures 2C, 3A,3D); U18666a
treatment for 24 h caused a relatively small decrease in glucose
transport and GLUT4 translocation, while Akt phosphorylation
was considerably reduced at this time point. Furthermore, the level
of insulin signalling is similar between 48 h and 72 h of U18666a
treatment, whereas it is between these time points that major
effects upon glucose uptake and GLUT4 translocation are
observed. One explanation for this is the redundancy within the
Akt signalling network. Only 5% of maximal Akt activation is
required to elicit full glucose transport effects [40]. Additionally,
disruption to other components comprising the insulin responsive
system may also account for this. We observed increasingly
aberrant GLUT4 trafficking over the 72 h U18666a treatment
(Figures 2A, B). This manifested itself as increased PM GLUT4 (as
a percentage of total levels) under unstimulated conditions and
reduced insulin stimulated GLUT4 PM levels (Figure 3D).
Decreased PM cholesterol has previously been reported to inhibit
GLUT4 internalisation, which may explain increased proportion
of total GLUT at the PM under basal conditions [41]. Further,
disruption of cholesterol trafficking has been found to reduce
SNARE machinery, specifically SNAP23 and syntaxin-4, at the
PM [42]. These SNAREs mediate GLUT4 fusion with the PM
[24] and thus impaired SNARE assembly at the PM or at other
cellular organelles [43] may contribute to the reduced GLUT4
translocation in U18666a treated cells (Figure 3C and D).
Although we observed modest effects on glucose transport at
times when signalling was reduced by U18666a (24 h) or siRNA-
mediated NPC1 knockdown, the major disruption of regulated
glucose transport only occurred in unison with large reductions in
GLUT4 protein levels (table 1). Considering these data, we
speculate that the metabolic complications associated with reduced
NPC1 expression [14,15] may be due, in part, to decreased
GLUT4 expression in adipose since adipose-specific KO of
GLUT4 confers insulin resistance and glucose intolerance [44].
Concomitant with decreases in GLUT4 gene expression, we
measured reduced in TFR but increased GLUT1 expression
(Figure 3B, C). Increased GLUT1 protein expression likely
explains raised basal 2-deoxyglucose uptake rates observed in
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U18666a treated cells (Figure 3A). Although we detected a defect
in GLUT4 trafficking in unstimulated cells under U18666a
treatment (Figure 3D) this probably does not contribute to
increased basal 2-deoxyglucose uptake as absolute levels of
GLUT4 at the PM were severely reduced (Figure 3C).
The effects of NPC1 inhibition described here are similar to
those described in cholesterol depleted adipocytes [45]. This
includes the change in expression of GLUT isoforms and
induction of insulin resistance. Reduced cholesterol availability
reduces LXR activity [46], which is a master transcriptional
regulator of cholesterol homeostasis. LXR has been reported to
regulate GLUT4 expression in adipocytes [27], and the LXR
target gene ABCA1 was reported to be down-regulated in
cholesterol depleted adipocytes that also displayed reduced
GLUT4 expression [45]. LXR activity was reduced in response
to U18666a, as measured by target gene expression levels. The use
of the LXR agonist GW3965 partially rescued the reduction in
GLUT4 gene expression (Figure 4F, G). In addition to GLUT4,
GLUT1 may also be LXR responsive. It has been shown
previously to respond to an LXR agonist [47]; we found that
GW3965 treatment similarly stimulated GLUT1 expression (data
not shown). However, it responds differently to canonical LXR
target genes in response to U18666a, suggesting that other
transcriptional regulators are at play. Nevertheless, it is clear that
changes in cholesterol homeostasis and LXR activity influence
adipocyte GLUT isoform expression.
The data presented here indicate that it is the change in
GLUT4 levels that has the biggest impact on insulin-regulated
glucose transport and that it is possible to achieve marked
reduction in Akt and AS160 phosphorylation without any major
impact on insulin-regulated glucose transport at high doses of
insulin. This is consistent with our previous work that highlights
the spareness in signalling components comprising the PI3K/Akt
signalling network [15,48]. However, such spareness does not exist
for GLUT4 and so models of GLUT4 repression are invariably
associated with defective insulin action at the level of insulin-
stimulated glucose transport. These include models of insulin
resistance in 3T3-L1 adipocytes [49–51], transgenic models in
mice [52], adipose tissue from insulin resistance mice [53] and
adipose tissue from insulin resistant humans [54].
Inhibiting NPC1 and so disrupting cholesterol trafficking in
3T3-L1 adipocytes resulted in a complex phenotype culminating
in a reduced response to insulin. Inhibiting NPC1 function
resulted in both reductions in IR and IRS1 proteins levels possibly
via instability created by disrupting cell surface lipid rafts and
reduced activation of Akt by upstream kinases again possibly due
to disruption of PM micro-domains. Further, it reduced GLUT4
levels partly through inhibition of LXR activity. Taken together,
our data reveal the importance of NPC1 activity in the
maintenance of adipocyte insulin sensitivity and implicates
cholesterol homeostasis in regulating several nodes of the insulin
response.
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